Vecuronium: a new nondepolarizing neuromuscular-blocking agent. Clinical pharmacology, pharmacokinetics, cardiovascular effects and use in special clinical situations.
Vecuronium provides additional flexibility to the clinician using neuromuscular-blocking drugs. Its shorter duration of action, lack of significant cardiovascular effects and lack of dependence on the kidney for elimination provide clinical advantages over, or alternatives to, currently available, nondepolarizing neuromuscular-blocking drugs.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000758:Anesthesia; D000773:Anesthesia, Obstetrical; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D002319:Cardiovascular System / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007700:Kinetics; D008875:Middle Aged; D003473:Neuromuscular Nondepolarizing Agents / Q000378:metabolism / Q000494:pharmacology*; D010197:Pancuronium / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology; D011247:Pregnancy; D013390:Succinylcholine / Q000494:pharmacology; D013997:Time Factors; D014673:Vecuronium Bromide
D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide; D013390:Succinylcholine; D010197:Pancuronium